Skip Nav Destination
Issues
1 June 2012
-
Cover Image
Cover Image
The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes in vitro via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1+, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1−. This strongly suggests that CEACAM1-mediated inhibition occurs in vivo and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Spotlight on Clinical Response
Review
Therapeutic Discovery
Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Rona Ortenberg; Yair Sapir; Lee Raz; Liat Hershkovitz; Ayelet Ben Arav; Sivan Sapoznik; Iris Barshack; Camila Avivi; Yackov Berkun; Michal J. Besser; Tehila Ben-Moshe; Jacob Schachter; Gal Markel
Preclinical Development
The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
Yan Ning; Melissa J. Labonte; Wu Zhang; Pierre O. Bohanes; Armin Gerger; Dongyun Yang; Leonor Benhaim; David Paez; David O. Rosenberg; Kalyan C. Nagulapalli Venkata; Stan G. Louie; Nicos A. Petasis; Robert D. Ladner; Heinz-Josef Lenz
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.